Waters Corporation Reports Strong First Quarter 2025 Financial Results

Details

GAAP earnings per share (EPS) were $2.03, and non-GAAP EPS was $2.25. The company raised its full-year 2025 constant currency sales growth guidance to +5.0% to +7.0% and non-GAAP EPS guidance to the range of $12.75 to $13.05. These results reflect strong instrument growth, particularly in the Pharma and Industrial end markets.

Items reported

Exhibits (1)

About Waters Corporation

Waters Corporation is a leading entity in the field of analytical instruments and software. It primarily focuses on providing laboratory solutions for a variety of sectors, including pharmaceuticals, healthcare, food and beverage, and chemical analysis. The company's offerings include high-performance liquid chromatography, mass spectrometry systems, and various supporting technologies used for advanced research in life sciences. Waters Corporation is pivotal in enhancing laboratory productivity, offering cutting-edge research tools that assist in drug development, quality control, and environmental testing. Operating globally, it serves a wide array of clients, including academic institutions, government agencies, and private industry players. With its commitment to innovation and precision, Waters Corporation plays a crucial role in advancing scientific and technological progress in multiple critical industries worldwide.